Infinium Peer Comparison

NSE: INFINIUM

₹261.70

₹-1.30 (-0.49%)

As on 01-Sep-2026IST

Market cap

₹408 Cr

Revenue (TTM)

₹156 Cr

P/E Ratio

33.6

P/B Ratio

3.7

Div. Yield

0 %

Edit

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	408	30,075	30,128	28,384	25,980
Revenue (₹ Cr)	156	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	7.84	414.00	288.22	-371.81	387.35
Net Margin (%)	4.97	11.23	14.79	-3.93	26.01
RoE (%)	9.32	8.38	29.77	-3.85	25.18
Price to Earnings	33.56	73.53	104.53	--	67.27
Price-To-Book	3.73	5.97	22.44	3.55	15.06

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	155.71	3,012.00	1,284.27	9,151.18	1,006.88
Total Income	157.83	3,074.00	1,296.22	9,312.95	1,023.80
Total Expenditure	139.23	2,619.00	1,028.33	7,733.31	774.80
EBITDA	16.48	393.00	255.95	1,417.87	232.07
Depreciation	3.29	217.00	36.59	816.34	26.62
EBIT	13.18	176.00	219.36	601.53	205.45
Interest	3.73	254.00	36.78	421.59	6.22
Other Income	2.12	62.00	11.95	161.77	16.93
Exceptional Items	--	--	--	--	--
Profit before Tax	11.57	-16.00	194.52	414.64	216.16
Provision for Tax	3.73	41.00	60.16	323.51	55.75
Profit after Tax	7.84	-57.00	134.36	91.13	160.42

Liabilities (₹ Cr)

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	109.46	4,353.00	540.98	8,125.47	1,309.63
Minority Interest	15.33	304.00	0.00	--	10.45
Non-Current Liabilities	9.85	887.00	122.65	3,392.72	26.93
Current Liabilities	63.59	2,042.00	786.03	3,850.56	202.25
Total Liabilities	198.39	8,100.00	1,451.43	15,513.53	1,549.26

Assets (₹ Cr)

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	58.32	5,017.00	386.29	9,487.47	757.63
Current Assets	139.92	2,465.00	1,063.37	5,881.28	791.64
Total Assets	198.39	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	51.85	1,859.00	393.17	4,720.27	8.18
Net Current Assets	76.33	423.00	277.34	2,030.72	589.39
Contingent Liabilities	--	770.26	12.25	99.76	15.38

Cashflow (₹ Cr)

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-29.12	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-27.24	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	79.29	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	22.93	-396.00	54.56	-25.99	155.52

Ratios

Profitability Ratios

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	13.23	4.07	26.97	6.61	20.14
ROE (%)	9.32	-1.48	30.68	1.14	16.19
ROA (%)	5.53	-0.78	10.50	0.60	12.13
EBIT Margin (%)	11.94	15.11	20.86	17.26	24.73
Net Margin (%)	4.97	-1.85	10.37	0.98	15.67
Cash Profit Margin (%)	7.15	4.14	7.13	8.54	18.58

Growth Ratios

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	14.78	7.65	50.40	11.99	40.34
EBIT Growth (%)	-7.35	272.95	54.77	15.16	83.12
Net Profit Growth (%)	-31.82	87.92	47.63	411.39	229.35
EPS Growth (%)	-35.64	90.35	45.69	410.84	67.16
Book Value Growth (%)	86.23	29.77	42.49	2.28	94.96

Valuation Ratios

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	46.28	0.00	0.00	326.26	62.97
Price / Book Value	3.44	5.31	0.00	3.69	15.26
Dividend Yield (%)	0.00	0.00	--	0.06	0.06
EV/EBITDA	21.19	54.36	1.09	21.49	79.31
Market Cap (₹ Cr)	376.96	23,064.69	0.00	29,731.27	19,988.69

Solvency Ratios

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.47	0.43	0.76	0.59	0.01
Short term debt to equity ratio	0.32	0.11	0.54	0.12	0.01
Current Ratio	2.20	1.21	1.35	1.53	3.91
Quick Ratio	1.50	0.85	0.69	0.93	3.02
Interest Coverage	4.10	0.94	6.29	1.98	35.76

Operating Efficiency Ratios

	Infinium	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	21.67	21.95	25.21	25.67	28.85
Asset Turnover	1.10	0.53	1.87	0.70	0.76
Receivable days	63.52	60.36	47.59	77.05	90.06
Inventory Days	80.81	64.42	62.58	77.13	61.02
Payable days	--	218.94	228.78	173.49	96.06
Cash Conversion Cycle	--	-94.15	-118.62	-19.30	55.02